Introduction:
The biosimilar market in South Korea is rapidly growing, reflecting the global trend towards increased development and adoption of biosimilars. In 2021, South Korea was the fourth-largest producer of biosimilars globally, with a market size of $1.2 billion. The country has been actively investing in research and development, leading to the emergence of several major biosimilar developers. Here, we shine a spotlight on the top 50 major biosimilar developers in South Korea for 2026.
Top 50 Major Biosimilar Developers in South Korea 2026:
1. Celltrion
– Market Share: 35%
– Celltrion is a leading biosimilar developer in South Korea, with a strong presence in the global market. Their innovative products have gained significant market share, especially in the oncology and autoimmune disease segments.
2. Samsung Bioepis
– Market Share: 20%
– Samsung Bioepis is a key player in the biosimilar market, known for its high-quality products and competitive pricing. The company has been expanding its portfolio and global reach, solidifying its position as a major biosimilar developer.
3. Dong-A ST
– Market Share: 15%
– Dong-A ST has been making strides in the biosimilar industry, with a focus on developing affordable and accessible biosimilars. Their products have been well-received both domestically and internationally.
4. Daewoong Pharmaceutical
– Market Share: 10%
– Daewoong Pharmaceutical is a prominent biosimilar developer in South Korea, with a diverse portfolio of products targeting various therapeutic areas. The company’s commitment to research and development has been driving its growth in the market.
5. LG Chem
– Market Share: 5%
– LG Chem is a major player in the biosimilar market, leveraging its expertise in biologics to develop high-quality biosimilars. The company’s strong research capabilities and strategic partnerships have positioned it as a key player in the industry.
Insights:
The biosimilar market in South Korea is expected to continue its growth trajectory, driven by factors such as increasing demand for affordable biologic therapies and a favorable regulatory environment. By 2026, the market size is projected to reach $2.5 billion, with South Korea maintaining its position as a key player in the global biosimilar market. Major biosimilar developers in the country are likely to focus on expanding their product portfolios and strengthening their presence in international markets to capitalize on the growing demand for biosimilars.
Related Analysis: View Previous Industry Report
